Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval

Bibliographic Details
Main Authors:	Kesselheim, Aaron S., Eddings, Wesley, Raj, Tara, Campbell, Eric G., Franklin, Jessica M., Ross, Kathryn M., Fulchino, Lisa A., Avorn, Jerry, Gagne, Joshua J.
Format:	Online
Language:	English
Published:	Public Library of Science 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074566/

Similar Items

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
by: Sarpatwari, Ameet, et al.
Published: (2015)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
by: Vatsan, Ramjay S, et al.
Published: (2013)

The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future
by: Xu, Joshua, et al.
Published: (2016)

Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis
by: Wang, Bo, et al.
Published: (2016)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
by: Kesselheim, Aaron S, et al.
Published: (2015)

OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
by: Kass-Hout, Taha A, et al.
Published: (2016)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
by: Degnan, Fred H.
Published: (2012)

FDA’s Nozzle Numerical Simulation Challenge: Non-Newtonian Fluid Effects and Blood Damage
by: Trias, Miquel, et al.
Published: (2014)

More Than 7 Years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications
by: Regier, Emily E., et al.
Published: (2016)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
by: Kramer, Judith M., et al.
Published: (2014)

Why Did the FDA Approve These Advertisements?
by: Oaks, David
Published: (2006)

Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review
by: Austad, Kirsten E., et al.
Published: (2011)

Clinicians’ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation
by: Kesselheim, Aaron S., et al.
Published: (2014)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Sakharkar, Meena K., et al.
Published: (2007)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Published: (2008-01-01)

Repurposing FDA-approved drugs for anti-aging therapies
by: Snell, Terry W., et al.
Published: (2016)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
by: Alam, Md Tausif, et al.
Published: (2014)

FDA approved drugs as potential Ebola treatments
by: Ekins, Sean, et al.
Published: (2015)

US FDA food contact approvals boost
Published: (1999)

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
by: Kesselheim, Aaron S., et al.
Published: (2012)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
by: Stanek, Eric J., et al.
Published: (2013)

Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study
by: Hwang, Thomas J, et al.
Published: (2016)

Regulatory Solutions to the Problem of High Generic Drug Costs
by: Luo, Jing, et al.
Published: (2015)

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
by: Wang, Bo, et al.
Published: (2015)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
by: Madrid, Peter B., et al.
Published: (2013)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
by: Vacchelli, Erika, et al.
Published: (2012)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
by: Mahajan, Rajiv
Published: (2013)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
by: Füzéry, Anna K, et al.
Published: (2013)

Larval Zebrafish Model for FDA-Approved Drug Repositioning for Tobacco Dependence Treatment
by: Cousin, Margot A., et al.
Published: (2014)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
by: Gayatri Ramakrishnan, et al.
Published: (2017-07-01)

Thalamotomy for essential tremor: FDA approval brings brain treatment with FUS to the clinic
by: Paul S. Fishman
Published: (2017-07-01)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
by: Kim, Kevin, et al.
Published: (2015)

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
by: Hou, Zhi-Jie, et al.
Published: (2015)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
by: Panic, Gordana, et al.
Published: (2015)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
by: Constantine, Ginger D., et al.
Published: (2016)

Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery
by: Colón, Jennifer M., et al.
Published: (2016)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
by: Zaidi, Asifa, et al.
Published: (2015)

Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
by: Kiseleva, Olga I., et al.
Published: (2015)

Possible FDA-approved drugs to treat Ebola virus infection
by: Yuan, Shu
Published: (2015)